Načítá se...

ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer

Although EZH2 enzymatic inhibitors have shown anti-tumor effects in EZH2-mutated lymphoma and ARID1A-mutated ovarian cancer, many cancers do not respond because EZH2 can promote cancer independently of its histone methyltransferase activity. Here we identify ZRANB1 as the EZH2 deubiquitinase. ZRANB1...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell Rep
Hlavní autoři: Zhang, Peijing, Xiao, Zhenna, Wang, Shouyu, Zhang, Mutian, Wei, Yongkun, Hang, Qinglei, Kim, Jongchan, Yao, Fan, Rodriguez-Aguayo, Cristian, Ton, Baochau N., Lee, Minjung, Wang, Yumeng, Zhou, Zhicheng, Zeng, Liyong, Hu, Xiaoyu, Lawhon, Sarah E., Siverly, Ashley N., Su, Xiaohua, Li, Jia, Xie, Xiaoping, Cheng, Xuhong, Liu, Liang-Chiu, Chang, Hui-Wen, Chiang, Shu-Fen, Lopez-Berestein, Gabriel, Sood, Anil K., Chen, Junjie, You, M. James, Sun, Shao-Cong, Liang, Han, Huang, Yun, Yang, Xianbin, Sun, Deqiang, Sun, Yutong, Hung, Mien-Chie, Ma, Li
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5933875/
https://ncbi.nlm.nih.gov/pubmed/29669287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2018.03.078
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!